Article By:
The Fly
Thursday, October 20, 2016 4:00 PM EDT
Piper Jaffray analyst David Amsellem told investors that Valeant Pharmaceuticals is likely to fall short of Wall Street expectations, adding that he would not be surprised to see the company make a "major downward revision" to its 2016 guidance.